

				
Published, ongoing & planned projects				
Title	Status	No.	Year	Download Link
AIHTA Project Reports				
Therapeutic conversation: The effectiveness of intensified physician-patient communication	published	1	2006	http://reports.aihta.at/22/
Horizon Scanning System (HSS) - An Overview	published	2	2006	http://reports.aihta.at/566/
External manual - Part 1	published	3	2007	http://reports.aihta.at/714/
Neonatal care of low-risk newborns - An approach to evidence-based health care planning in Styria	published	4	2007	http://reports.aihta.at/693/
Role and positioning of university outpatient departments	published	5	2007	http://reports.aihta.at/65/
Internal manual - Part 2 (2nd Ed.)	published	6	2009	http://reports.aihta.at/713/
Mammography screening - Evidence-based evaluation of mammography-based breast cancer screening programmes	published	7	2007	http://reports.aihta.at/715/
Testing for HER2 positive breast cancer - Challenge for improvement of current conditions and practice	published	8	2007	http://reports.aihta.at/716/
Economic evaluation of HPV vaccination in Austria	published	9	2007	http://reports.aihta.at/760/
Economic aspects of clinically effective and efficient models of health services in alcohol addiction treatment - Part 1: International models and approaches of outcome measurement, Part 2: Selected models of integrated care and their evaluation - Part 3: ongoing	published	10	2009	http://reports.aihta.at/823/
Clinical and health economic registries in the field of cardiovascular, spinal and neurologic diseases. Methods and good practice strategies	published	11	2008	http://reports.aihta.at/788/
Back pain - Diagnosis and treatment according to evidence-based guidelines - options and limitations	published	12	2008	http://reports.aihta.at/794/
Clinical application of Tissue Engineering - An overview of International and Austrian Areas of Research with a critical analysis of selected applications	published	13	2008	http://reports.aihta.at/807/
Horizon Scanning in Oncology - Concept Development for the Preparation of a Horizon Scanning System in Austria	published	14	2008	http://reports.aihta.at/798/
Outpatient Cardiac Rehabilitation - Part 1: Evaluation and Indicators - Part 2: Comparative analysis of various rehabilitation models and Phase III	published	15	2008	http://reports.aihta.at/800/
Clinical Pathways: Systematic Review of outcome parameters and effectiveness	published	16	2008	http://reports.aihta.at/801/
Cervical Fractures - A systematic review about efficacy and safety of different treatment options	published	17	2008	http://reports.aihta.at/816/
Stains for the Secondary Prevention of Cardiovascular Diseases: An Analysis of Expected Population Health Gains and Cost/Utility in Austria (Part 2 of the project 'Stains: A comparison between predicted and actual effects on population health in Austria)	published	18	2008	http://reports.aihta.at/803/
Have Stains Met Our Expectations? A Comparison of Expected Health Gains from Stains with Epidemiological Trends in Austria (Part 3 of the Project 'Stains: A Comparison between Predicted and Actual Effects on Population Health in Austria')	published	19	2008	http://reports.aihta.at/804/
Folic acid fortification of flour in Austria - Risks and benefits	published	20	2009	http://reports.aihta.at/847/
Evidence supported health service planning	published	21	2009	http://reports.aihta.at/843/
Reimbursement processes - An analysis of international practice models for maintaining the health benefit baskets of solidly financed health care systems	published	22	2008	http://reports.aihta.at/817/
Classification of disease severity for neuro- and trauma rehabilitation - Part 1: Instruments for stroke and traumatic brain injury	published	23a	2009	http://reports.aihta.at/866/
Classification of disease severity for neuro- and trauma rehabilitation - Part 2: International experiences with quality / performance assessments and reimbursement	published	23b	2009	http://reports.aihta.at/867/
Classification of disease severity for neuro- and trauma rehabilitation - Part 3: Status quo in Austria	published	23c	2010	http://reports.aihta.at/879/
Coverage with Evidence Development - Experiences from selected countries	published	24	2009	http://reports.aihta.at/818/
Kyphoplasty and vertebroplasty for the treatment of osteoporotic vertebral compression fractures: observational study	published	25	2010	http://reports.aihta.at/900/
Developing a decision aid on HPV vaccination for young girls and women/ mothers	published	26	2009	http://www.fhpv-entscheidungsstille.de
Evaluations of child and adolescent psychiatry (Part 1a) - Theory and practice about measurement dimensions, indicators and instruments	published	27	2009	http://reports.aihta.at/846/
Child and adolescent psychiatry (Part 1b) - A systematic review of health economic evaluations	published	28	2009	http://reports.aihta.at/862/
Child and adolescent psychiatry (Part 2) - Evaluation study at the University Department of Child and Adolescent Psychiatry (Christian-Doppler-Klinik) in Salzburg	published	40	2010	http://reports.aihta.at/862/
Telemedicine in Stroke Management - Systematic Review	published	29	2009	http://reports.aihta.at/844/
Toxolysin in preterm labour - A systematic review of evidence-based guidelines, effectiveness and health economic evaluations	published	30	2009	http://reports.aihta.at/825/
Outpatient cardiac rehabilitation - Part 3a: Retrospective cohort study (with/without phase II rehabilitation - Explorative analysis and developing of an evaluation plan	published	31a	2010	http://reports.aihta.at/875/
Outpatient cardiac rehabilitation - Part 3b: Retrospective cohort study (with/without phase III rehabilitation - Application of the evaluation plan	published	31b	2010	http://reports.aihta.at/876/
Horizon scanning in ophthalmology - Part 2: From pilot to routine	ongoing	32		reports.aihta@onion.net
Artificial food colours and Microplastic	published	34	2009	http://reports.aihta.at/849/
Status quo Mammography screening - Evaluation results from organised programs	published	35	2009	http://reports.aihta.at/863/

Title	Status	No.	Year	DownloadLink
Evaluation of diagnostic technologies – background, challenges, methods	published	36	2010	http://eprints.ahtia.at/898/
Impact from HTA-research for the Austrian health care system. Part 1: Overview - Update	published	37a	2010	http://eprints.ahtia.at/877/
Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey	published	37b	2011	http://eprints.ahtia.at/907/
Acquisition Processes of Certain Product Groups in Hospitals - Orthopaedic and Cardiac Treatments	published	38	2009	http://eprints.ahtia.at/864/
Use of Clozapine P and Flanserin P in acute psychiatric inpatient	published	39	2009	http://eprints.ahtia.at/870/
Screening for Colorectal Cancer. Part 1: Screening-Tests and Protocol Design	published	41a	2010	http://eprints.ahtia.at/873/
Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs	published	41b	2010	http://eprints.ahtia.at/874/
IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Principles of standardised work in HTA (WPI 2)	published	44a	2011	http://eprints.ahtia.at/932/
IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Glossary of terms (WPI 1)	finished	44b	2011	not published
Reorientation of the Austrian parent-child preventive care programme. Part 1: Epidemiology - incidence of risk factors and diseases in pregnancy and early childhood	published	45a	2011	http://eprints.ahtia.at/912/
Reorientation of the Austrian parent-child preventive care programme. Part 2: International Policies, approaches and screening strategies to "normal" and "risk experiences" during pregnancy and early childhood to school entry	published	45b	2011	http://eprints.ahtia.at/913/
Reorientation of the Austrian parent-child preventive care programme. Part 3: Status quo of the financing and cost structures of parent-child services in Austria	published	45c	2011	http://eprints.ahtia.at/914/
Reorientation of the Austrian parent-child preventive care programme. Part 4: Synthesis of Parts 1-3. Recommendations	published	45d	2011	http://eprints.ahtia.at/915/
Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications	published	47	2010	http://eprints.ahtia.at/951/
Strengthening the evidence base for a learning health system - Innovations from good practice for capacity building in health services research and public health research	published	48	2011	http://eprints.ahtia.at/908/
Quality of care in oncology and its measurement	published	49a	2011	http://eprints.ahtia.at/934/
Genetic indicators for process quality in oncological care. A compendium	published	49b	2012	http://eprints.ahtia.at/946/
Reorientation of the Austrian parent-child preventive care programme. Part 6: Preterm birth	published	50	2012	http://eprints.ahtia.at/939/
Systematic review of the efficacy and safety of treatments for varicose veins of the lower extremity	published	51	2011	http://eprints.ahtia.at/930/
Assessment of the quality and accuracy of written consumer health information for patients with chronic myeloid leukaemia on treatment regimens with dasatinib, imatinib or nilotinib	published	52	2012	http://eprints.ahtia.at/950/
Reorientation of the Austrian parent-child preventive care programme. Part 6: Health visitors services in the international context and implementation options for Austria	published	53	2012	http://eprints.ahtia.at/947/
Reorientation of the Austrian parent-child preventive care programme. Part 7: Options for an electronic implementation	published	54	2012	http://eprints.ahtia.at/948/
Reorientation of the Austrian parent-child preventive care programme. Part 8: Budget Impact Analysis	published	55	2012	http://eprints.ahtia.at/949/
Occupational therapy in Austria	published	56	2012	http://eprints.ahtia.at/972/
Disinvestment: Overview of disinvestment experiences and challenges in selected countries	published	57	2011	http://eprints.ahtia.at/926/
Standards on how to incorporate models via published literature - Input of the LBI HTA for IFEDH workpackage 4	published	58	2012	http://eprints.ahtia.at/990/
Occupational therapy Part 3 - Occupational therapy for patients after stroke	published	59	2012	http://eprints.ahtia.at/973/
Occupational therapy Part 4 for Dementia and Part V for Depression	published	60	2012	http://eprints.ahtia.at/974/
Horizon Scanning in Oncology - Impact Evaluation	published	61	2012	http://eprints.ahtia.at/969/
Reorientation of the Austrian parent-child preventive care programme - Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)	published	62	2013	http://eprints.ahtia.at/996/
(B) Health and access to health care in homeless people: A literature review	published	63	2012	http://eprints.ahtia.at/940/
Day Surgery: A Systematic Overview	published	64	2012	http://eprints.ahtia.at/987/
Screening for Colorectal Cancer. Part 1: Screening-Tests and Program Design (3, updated edition)	published	41a	2012	http://eprints.ahtia.at/981/
Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2, updated edition)	published	41b	2012	http://eprints.ahtia.at/982/
Screening for Colorectal Cancer. Part 3: update von Teil 1 (41 a) und Teil 2 (41 b). Quality of screening colonoscopy	published	41c	2013	http://eprints.ahtia.at/983/
Marketing Authorizations under Exceptional Circumstances for Oncology Drugs	published	65	2013	http://eprints.ahtia.at/992/
Outpatient cardiac rehabilitation: Part 6: Scientific monitoring of the "Multi-centre, prospective cohort study with two control groups (with/without phase III)"	abgeschlossen	66		not published
Mental Health: rehabilitation for children and adolescents - A literature overview on indications, outcomes and evaluation instruments	published	67	2013	http://eprints.ahtia.at/1012/
Identifying ineffective interventions and health technologies: models and their implementation	published	68	2013	http://eprints.ahtia.at/1014/
Treatment by clinical psychologists. Part 1: Overview of training requirements and systematic stakeholder analysis on delineation of areas of responsibility and treatment methods	published	69a	2013	http://eprints.ahtia.at/1018/
Treatment by clinical psychologists. Part 2: Literature overview on methods of treatment and areas of application	published	69b	2013	http://eprints.ahtia.at/1019/
Occupational therapy in children. Part 1 - Literature review on indications, utilisation and recommendations	published	70	2013	http://eprints.ahtia.at/1016/
Cost- and Budget Impact Analysis of an Increase in Day Surgery for Selected Indications	published	71	2014	http://eprints.ahtia.at/1035/
p16/R6/67 Dual Stain in cytological screening of cervical cancer: A systematic literature review of clinical studies based on a review of methodological approaches for assessing biomarkers	published	72	2013	http://eprints.ahtia.at/1009/
Evidence requirements for the authorisation and reimbursement of high risk medical devices in USA, Australia and Canada	published	73	2013	http://eprints.ahtia.at/1017/
Proton and Carbon Ion therapy	published	74	2013	http://eprints.ahtia.at/1021/
Sustainability of inpatient psychiatric rehabilitation for adults: systematic review	published	75	2014	http://eprints.ahtia.at/1022/
Positron emission tomography/ Computed tomography (PET/CT): need assessment for planning	published	77	2015	http://eprints.ahtia.at/1045/

Title	Status	No.	Year	DownloadLink
Announcement - areas of application, current evidence and proven indications	published	78	2014	http://reports.ahha.at/1042/
Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids	published	79	2014	http://reports.ahha.at/1043/
Criteria and recommendations for an adequate use of Magnetic Resonance Imaging (MRI)	published	80	2014	http://reports.ahha.at/1043/
Lithuania HTA Training	finished	81		not published
Advances of MRI 2	finished	82		not published
Effects of (f)inancial incentives on health behaviour. Part I: Definitions, theories and models and Part II: Overview of reviews covering 4 health issues	published	83	2015	http://reports.ahha.at/1078/
Robotic Surgery	published	84	2015	http://reports.ahha.at/1077/
Endovascular stroke therapy	finished	85		not published
Patient- and citizen participation in HTA processes - Good Practice	published	86	2016	http://reports.ahha.at/1088/
Nudging - Behavioral Sciences applied to the Rio Four Public Health Issues	published	83/ Addendum	2015	http://reports.ahha.at/1078/
Mechanical thrombolysis in acute ischemic stroke. Patient characteristics, structural requirements and (differential) diagnosis	published	87	2016	http://reports.ahha.at/1164/
New concept for primary care (Supply mandates)	published	88	2016	http://reports.ahha.at/1110/
Outpatient cardiac rehabilitation. Part 6: Economic evaluation	published	89	2016	http://reports.ahha.at/1102/
Options to identify inappropriate use of MRI. Part 3	published	80c	2015	http://reports.ahha.at/1158/
Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2	published	80b	2015	http://reports.ahha.at/1090/
Outpatient cardiac rehabilitation. Part 6: Scientific monitoring of the Multi-centre, consecutive cohort study with two control groups (with/without chase III)	published	90	2016	http://reports.ahha.at/1101/
Reorientation of the Austrian parent-child preventive care programme. Part 12: Economic evaluation of selected screenings, during pregnancy	published	91	2017	http://reports.ahha.at/1198/
Reorientation of the Austrian parent-child preventive care programme. Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)	published	82a/ update 2016	2016	http://reports.ahha.at/1112/
Re-orientation of the Austrian parent-child preventive care programme. Part 11: Screening recommendations of the expert working group for pregnancy	published	92	2019	http://reports.ahha.at/1163/
Locally recognized psychotherapy methods in Austria – effect factors, indications, setting specific aspects	published	93	2017	http://reports.ahha.at/1143/
Telekardiologie - Map O and evaluation methods: Work in Progress	finished	94		not published
Transcatheter Aortic Valve Implantation Part 1: A systematic review of economic evaluations	published	95a	2017	http://reports.ahha.at/1139/
Social Return on Investment for Child and Adolescence Health: Outcomes, Methods and Economic Parameters	published	96	2017	http://reports.ahha.at/1142/
Perinatal Care at the threshold of viability. Part I (Resource planning for Neonatal Care Units: clinical outcomes and resource needs. Part II (Good) Practice Models to handle Ethical, Organizational, and Social Challenges	published	97a	2018	http://reports.ahha.at/1146/
Perinatal Care at the threshold of viability. Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs)	published	97b	2018	http://reports.ahha.at/1146/
Transcatheter Aortic Valve Implantation (TAVI) Part 1: Use in Austria and Guideline Recommendations for Appropriate Use	published	98	2018	http://reports.ahha.at/1150/
Transcatheter Aortic Valve Implantation (TAVI) Part 2: Frequency, Patient Collective, and Geographic Variation Over Time in Austria	published	95b	2017	http://reports.ahha.at/1141/
PET/PET-CT Evidence for need based planning in Germany and Austria	published	77a/ update 2018	2018	http://reports.ahha.at/1178/
Dropouts in psychotherapies – Theoretical reflections and counter-strategies	published	100	2018	http://reports.ahha.at/1157/
Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications	published	101	2018	http://reports.ahha.at/1174/
Genexpressionsel Mammographie zur Entscheidungsunterstützung bei prämenopausaler Chemotherapie bei primärem Brustkrebs	published	102	2018	http://reports.ahha.at/1147/
Screening of fetal incomes 21, 18 and 15 by zoonomye amniotale flüssigkeit	published	103	2018	http://reports.ahha.at/1153/
Inhalation sedation with laughing gas (N ₂ O) in dentistry – organizational and professional aspects and a systematic review of efficacy and safety	published	105	2018	http://reports.ahha.at/1182/
Screening programmes for children and adolescents aged 6-14 years in selected countries and recommendations from evidence-based guidelines	published	106	2018	http://reports.ahha.at/1212/
Stereotactic radiotherapy (Stereotaktische) proton beam therapy and irreversible electroporation (Nanokniffe) for localised prostate cancer (PCa): a systematic review	published	107	2018	http://reports.ahha.at/1165/
Robot-assisted surgery: A systematic review of effectiveness and safety in thoracic and visceral surgery	published	108	2019	http://reports.ahha.at/1198/
Pricing and reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process taking into account international experience	published	109	2019	http://reports.ahha.at/1183/
EdiTechology: Personalized advanced therapies in late clinical research: EMA approval or clinical application via hospital exemption	published	111	2019	http://reports.ahha.at/1197/
Natalizumab as treatment for Multiple Sclerosis: a systematic review	published	112	2019	http://reports.ahha.at/1190/
Uptake of mental health care benefits (co-) funded by the Tyrolean health insurance (Vilage)	published	113a	2019	http://reports.ahha.at/1181/
Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance	published	113b	2019	http://reports.ahha.at/1181/
Evaluation methods for benefit assessment of easily accessible outpatient health centres for vulnerable groups - Focus: homeless and uninsured persons	published	114	2019	http://reports.ahha.at/1195/
Transcatheter aortic valve implantation (TAVI) for the treatment of patients at intermediate surgical risk: TRANSCATHER AORTIC VALVE IMPLANTATION (TAVI)	published	115	2019	http://reports.ahha.at/1188/
Comparative system point-of-care testing (POC-PSA) to guide antibiotic prescriptions in primary care settings for acute respiratory tract infections. EUnetHTA-Report	published	116	2019	http://reports.ahha.at/1194/
3D-Druck von Makrostrukturen oder individualisierten Implantaten und Schnittschablonen. EUnetHTA-Report	published	117	2019	http://reports.ahha.at/1209/
Screening for Diabetes mellitus: guideline recommendations	published	118	2019	http://reports.ahha.at/1213/

Title	Status	No.	Year	DownloadLink
Irreversible Elektroporation (IRE) bei Bauchspeicheldrüsen- und Leberkrebs. E.UHealth-Report	published	119	2019	http://reports.aitha.at/1211/
Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies	published	120	2019	https://reports.aitha.at/1214/
Prevention of cervical cancer in Austria – Implementation of HPV testing into the existing screening programme	published	121	2019	https://reports.aitha.at/1223/
Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies	published	122	2019	https://reports.aitha.at/1222/
Screening programmes for children and adolescents – aged 6-18 years. Part 1	finished	123		not published
POCT/ Point of Care Tests: D-Dimer und Troponin	published	124	2019	https://reports.aitha.at/1224/
Minimum volume standards for quality assurance in day surgery	published	125	2019	https://reports.aitha.at/1225/
Health Services Research in Oncology: Patients with Non-small Cell Lung Cancer (NSCLC) treated with Anti-PD1/PD-L1 Therapy in Real-World Practice	published	126	2020	https://reports.aitha.at/1227/
Health Services Research in Oncology Part 1: End-of-Life Care	published	127	2020	https://reports.aitha.at/1233/
Robotic and functional electrical stimulation for stroke rehabilitation	published	128	2020	https://reports.aitha.at/1302/
Home treatment in child and adolescent psychiatry: An analysis of effectiveness and integrated care	published	129	2020	https://reports.aitha.at/1275/
Molecular genetic diagnostics as a biopsy mechanism in cardiology using the example of familial hypercholesterolemia: Organisational and ethical implications (part 1) and economic effects (part 2)	published	130	2020	https://reports.aitha.at/1281/
Lung cancer screening in risk groups. Systematic review(s) of effectiveness and utility (part 1)	published	132a	2020	https://reports.aitha.at/1282/
Lung cancer screening in risk groups. Systematic review(s) of Costs and budgetary consequences (part 2)	published	132b	2020	https://reports.aitha.at/1283/
Effectiveness of music therapy	published	133	2020	https://reports.aitha.at/1280/
Frameworks for reimbursement decisions of digital health technologies (in health) and its retrospective application on selected examples	published	134	2020	https://reports.aitha.at/1279/
Epidemiology of new COVID-19 infections: report. German short version of the original KGE report	published	135a	2021	https://reports.aitha.at/1321/
Lone COVID care pathways: a systematic review	published	135b	2021	https://reports.aitha.at/1342/
Evidence-based reimbursement processes in Europe Part 1: Reimbursement decisions for medical procedures in Austria. An analysis of factors – besides clinical evidence – influencing reimbursement decisions for the hospital benefit calculation	finished	136		not published
Evidence-based reimbursement processes in Europe Part 2: A comparative analysis of selected medical devices in German and Austrian hospitals and possible influencing factors	finished	137		not published
(Good) practice quantitative models using real-world evidence for public funding of high priced therapies	published	138	2021	https://reports.aitha.at/1320/
National strategies and programmes for preventing and managing non-communicable diseases in selected countries	published	139		https://reports.aitha.at/1349/
Contrasting evidence from pivotal trials with real world evidence for treatment with nivolumab in malignant melanoma	published	140	2021	https://reports.aitha.at/1341/
Process and evaluation of digital health applications in the context of "Symptom Checkers"	published	141	2021	https://reports.aitha.at/1348/
The economic and societal dimension of mental health illness	published	142	2021	https://reports.aitha.at/1351/
Telemonitoring in Austrian diabetes care: A systematic analysis of evaluation methodologies	published	143	2022	https://reports.aitha.at/1370/
Osteopathy, effectiveness and safety for musculoskeletal pain and overview of training and quality requirements	published	144	2022	https://reports.aitha.at/1416/
Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess the individual breast cancer risk, their utility and applicability in breast cancer screening programs	published	145	2022	https://reports.aitha.at/1402/
CAR-T cell therapies (axicabtagene ciloleucel/ Yescarta®) or tisagenlecleucel/ Kymriah®): Contrasting pivotal studies with data from utility studies	published	146	2022	https://reports.aitha.at/1415/
Lone Covid – Versorgungspläne und Versorgungsstrukturen Update	published	135b/Update	2022	https://reports.aitha.at/1408/
Support for children with mental ill parents in Tyrol: Summary results of the Village Project	finished	147		not published
Perinatal and infant mental health care models and pathways	published	148	2022	https://reports.aitha.at/1420/
Child and adolescent mental health care models	published	149	2022	https://reports.aitha.at/1419/
Quality Registries in Dementia Care: Mapping of Registries to improve Quality and Service Delivery	published	150	2022	https://reports.aitha.at/1419/
Perinatal and infant mental health care in Austria: A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol	published	151	2023	https://reports.aitha.at/1437/
Oral and parenteral pre-exposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements	published	152	2023	https://reports.aitha.at/1438/
Robot-assisted surgery: A systematic review of effectiveness and safety in thoracic and visceral surgery. Update 2023	published	108/Update 2023	2023	https://reports.aitha.at/1461/
Economic dimensions of community nursing	published	153	2023	https://reports.aitha.at/1478/
Mental health Services Uptake in Women Before and During Pregnancy until One Year after Birth: An Analysis of Austrian Health Insurance Data (im Rahmen des FWF Projektes 'Connected Minds' exist)	published	154	2023	https://reports.aitha.at/1535/
Review of strategies regarding target group accessibility, participation motivation, and adherence in prevention programmes for overweight or obese children, adolescents, and adults	published	155	2023	https://reports.aitha.at/1480/
Image-guided spinal injections in treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques	published	156	2023	https://reports.aitha.at/1477/
Registries in Austria and their usage for healthcare improvement	published	157	2023	https://reports.aitha.at/1489/
The Role of Public Contributions to the Development of Health Innovations	published	158	2024	https://reports.aitha.at/1499/
Point of Care Tests (POCT): D-Dimer and Troponin. Update 2024	published	1. Update 2024	2024	https://reports.aitha.at/1526/
Stereotactic radiotherapy, proton therapy and irreversible electrocoagulation for the treatment of localised prostate cancer	published	107/1. Update	2024	https://reports.aitha.at/1530/

Title	Status	No.	Year	DownloadLink
Mental health screening of adults in primary care	published	159	2024	https://reports.aitha.at/1544
Strategies to reduce weight stigmatisation of people with overweight or obesity in the healthcare sector	published	160	2024	https://reports.aitha.at/1547
ASSESS-DHT: Telehealth in diabetes: EU mapping and systematic evaluation of organisational aspects	ongoing	161		https://reports.aitha.at/1555
Optimising Breast Cancer Care in Selected European Countries - Organisation of healthcare infrastructures and medical service provision	published	162	2024	https://reports.aitha.at/1545
Threshold values in health economic evaluations and decision-making	published	163	2024	https://reports.aitha.at/1549
Artificial Intelligence in health care with a focus on hospitals: Methodological considerations for Health Technology Assessment: A Scoping Review	published	164	2024	https://reports.aitha.at/1546
Trauma Care: Teaching Recovery Technique (TRT) to refugees: Systematic Review and Evaluation of Austrian TRT-Programme at AFYA	published	165	2025	https://reports.aitha.at/1563
CAR-T cell therapy: Updated effectiveness and safety results from real-world evidence	published	166	2025	https://reports.aitha.at/1562
Digital health technologies for self-identification of the risk of perinatal mental illness	published	167	2025	https://reports.aitha.at/1571
Nudges to Optimize Prescriber Behavior of Physicians	published	168	2025	https://reports.aitha.at/1593
Systematic Review of the Long-Term Effectiveness and Safety of Enzyme Replacement Therapy in Mucopolysaccharidosis Disorders and Pompe Disease	ongoing	169		
Further Development of the Program on Preventiv. Brief interventions for lifestyle counselling: Umbrella review and qualitative survey Medical Check-Ups in Austria	published	170a	2025	https://reports.aitha.at/1576
Further Development of the Programme on Preventive Health Check-Ups: Risk Scores for Cardiovascular Disease: A Systematic Review	published	170b	2025	https://reports.aitha.at/1577
Further Development of the Program on Preventive Health Check-Ups: Screening for Chronic Kidney Disease - a rapid review on benefits, harms and target populations	published	170c	2025	https://reports.aitha.at/1573
Artificial Intelligence for Hospital Documentation Support - A Scoping Review of Current Use Cases	published	171a	2026	https://reports.aitha.at/1597
AI-supported Chest X-Ray Analysis for Lung Cancer Detection: Systematic Review of clinical outcomes and organisational implications	published	171b	2026	https://reports.aitha.at/1598
Telekardiologie bei Herzinsuffizienz: Evidenzbewertung und Evaluationskonzept für telemedizinisch unterstützte Versorgungsprogramme in Österreich	published	172	2025	https://reports.aitha.at/1584
Social Prescribing in Primary Care - Development of an Austrian programme theory based on realist evidence	published	173	2025	https://reports.aitha.at/1581
Health Economic Reference Cases and Costing Approaches - Concepts, International Practices and Implications for Austria	ongoing	174	2026	https://reports.aitha.at/1601
Structured Medication Review for Polypharmacy - Systematic Review	ongoing	175	2026	https://reports.aitha.at/1600
Genetische Untersuchungen in Österreich - Teil A: Anamneseziele, internationale Erstattungsprozesse und Priorisierungskriterien	published	176a	2026	https://reports.aitha.at/1602
Genetic Testing in Austria - Part B: Carrier Screening for Selected Genetic Conditions	published	176b	2026	https://reports.aitha.at/1603
Genetic Testing in Austria - Part C: Detection of PKC3/CAK1/IPTEN/ESR1 genetic alterations in HR+/HER2- breast cancer	published	176c	2026	https://reports.aitha.at/1604
Transition from Child and Adolescent to Adult Mental Health Services: Analysis and Comparison of International Models	published	177	2025	https://reports.aitha.at/1574
FALCO: Fighting Addictions, improving Lives: Comprehensive drug rehabilitation with music (Suchterkrankungen bekämpfen, Leben verbessern: Umfassende Rehabilitation durch Musik bei Personen mit Suchterkrankungen)	ongoing	178		
Guidance for Searching and Finding Public contributions to oha-maccedical R&D	ongoing	179		
Health navigators	ongoing	180		
Preparatory work for Austrian health economic guidelines - review of processes (development, dissemination, implementation, monitoring)	ongoing	181a		
Preparatory work for Austrian health economic guidelines - overview of health economic guidelines	ongoing	181b		
Combination Therapy with Antidepressants and Vitamin B Complex Compared to Antidepressant Monotherapy	ongoing	182		

Title	Status	No.	Year	DownloadLink
Rapid Assessments				
Drug eluting stents in comparison to uncoated stents in the treatment of cardiopathy	published	1	2006	http://reports.ahta.at/34/
Avastin® for age-related macular degeneration	published	2	2007	http://reports.ahta.at/748/
Rational Vaccination Policies - decision support - Review of International Literature for "Rational" Vaccination Policies	published	3	2008	http://reports.ahta.at/741/
Sacral Nerve Stimulation for Fecal Incontinence	published	4	2011	http://reports.ahta.at/955/
Avastin® for age-related macular degeneration: Gutachten zu Stand des Wissens	published	5	2012	http://reports.ahta.at/989/
Hypnot-Operation rooms	published	6	2013	http://reports.ahta.at/995/
Transparency: continuing medical education and NIS database	published	7a	2015	http://reports.ahta.at/1053/
Transparency: continuing medical education/observational study and NIS database	published	7b	2015	http://reports.ahta.at/1072/
Transparency: continuing medical education/observational study and NIS database	published	7c	2016	http://reports.ahta.at/1150/
Pharma: Disclosure of transfers of value in Austria 2015	published	7d	2017	http://reports.ahta.at/1107/
Drugs in Oncology: an overview of benefit and refund practices in Europe	published	8	2016	http://reports.ahta.at/1091/
HTAs on Medical Devices and Procedures in Europe: Timing, Risk-Classes, Product-Groups, Assessments	published	12	2016	http://reports.ahta.at/1108/
Importance and transparency of non-interventional drug studies (NIS) in selected countries: A comparison with Austria	published	7c1 Update 2017	2017	http://reports.ahta.at/1122/
Sponsoring of Patient Initiatives in Austria 2015. Update of the Systematic Analysis 2014	published	7b1 Update 2017	2017	http://reports.ahta.at/1125/
Sponsoring of Patient Initiatives in Austria 2016. Update of the Systematic Analysis 2015 and 2014	published	7b2 Update 2017	2017	http://reports.ahta.at/1132/
MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EuroHTA report	published	13	2018	http://reports.ahta.at/1147/
FoundationOneCDx: Bestimmung von genetischen Profilen solider Tumore	published	14	2019	http://reports.ahta.at/1215/
Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016	published	7b3 Update 2017	2019	http://reports.ahta.at/1217/
Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015	published	7d1 Update 2019	2019	http://reports.ahta.at/1218/
Policy Briefs				
Update 19 Monate Nachbeobachtung. Nutzen von Soziale Muskelatrophie („Jale onse“) bei Kindern und Jugendlichen 3-8 Jahre	published	1	2020	http://reports.ahta.at/1228/
Covid-19: HSI/ Horizon Scanning Living Document (Part 1 & Part 2)	published	2	2020	http://reports.ahta.at/1234/
PET-Indikationen	published	3	2020	http://reports.ahta.at/1249/
Update: Proton- and Carbon Ion Therapy	published	4	2020	http://reports.ahta.at/1245/
Parent/Child-Pass Update 2020/21 - Screenings for mental health, nutrition and social competence – recommendations from evidence-based guidelines	published	5	2021	http://reports.ahta.at/1303/
Ca-T Cell Therapies	published	6a	2020	http://reports.ahta.at/1268/
ATMPs and Gene Therapies	published	6b	2020	http://reports.ahta.at/1269/
Transparency: Sponsoring of patient initiatives. Update	published	7	2021	http://reports.ahta.at/1308/
Combinationstherapie Casirivimab plus Imdevimab (REGN-COV2) for the treatment of covid-19	published	8	2021	http://reports.ahta.at/1313/
Bamlanivimab monotherapy and as combination therapy (with etesevimab) for Covid-19	published	9	2021	http://reports.ahta.at/1314/
Nicht-Interventionelle Studien (NIS) in Österreich	published	10	2021	http://reports.ahta.at/1333/
Stool DNA testing for colorectal cancer (CRC) screening	published	11	2021	http://reports.ahta.at/1335/
3-12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies	published	11 Update 2021	2021	http://reports.ahta.at/1352/
Recall and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries	published	12	2022	http://reports.ahta.at/1368/
Ca-T Cell Therapies	published	6a Update 2022	2022	http://reports.ahta.at/1368/
ATMPs and Gene Therapies in Development: Horizon Scanning – Update 2022	published	6b Update 2022	2022	http://reports.ahta.at/1383/
Update PET/PET-CT: Evidenz zum Bedarf und zur Planung bei onkologischen Indikationen. Update 2023	published	3 Update 2023	2023	http://reports.ahta.at/1442/
Sponsoring of patient initiatives in Austria. 5th Update of the Systematic Analyses 2014 to 2019. AHTA Policy Brief 007/5. Update	published	7a Update 2023	2023	http://reports.ahta.at/1443/
SMA Therapies: Mittel- bis längerfristige Nachbeobachtung von SMA-Patient*innen, behandelt für >=24 Monate mit Nusinersen oder Onasemnogene Apepavone, und für >=12 Monate mit Risdiplam (Mono- (Kombinations)therapien)	published	1, 2 Update	2023	http://reports.ahta.at/1485/
Assessment of study report: The Improve Drug Therapy Trial	ongoing	13		
Decision Support Document for the Austrian Aorazal Board				
Exagamglogene autolemozel (Exa-cel, Casoev®) zur Behandlung von Beta-Thalassämie und schwerer Sichelzellerkrankheit	published	1	2025	http://reports.ahta.at/1549/
Fidanogogene elacavovec (BEQVEZ®) for the treatment of moderate and severe haemophilia B	published	2	2025	http://reports.ahta.at/1558/
Exagamglogene autolemozel (Exa-cel, Casoev®) for the treatment of beta-thalassemia and severe sickle cell disease	published	3	2025	http://reports.ahta.at/1550/
Lifileucel (AMTACV®) for previously treated unresectable or metastatic melanoma	published	4	2025	http://reports.ahta.at/1570/
Obecabtagene autolemozel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia	published	5	2025	http://reports.ahta.at/1589/
Decision Support Documents				
Photoselective vaporisation of the prostate in men with benign prostatic hyperplasia	published	1	2007	http://reports.ahta.at/747/
Targeted radiorisidate therapy with 90Y- and 177Lu-DOTA-TOC in patients with neuroendocrine tumors	published	2	2007	http://reports.ahta.at/749/
Photodynamic therapy for the treatment of malignant stenosis in the alimentary tract	published	3	2007	http://reports.ahta.at/851/
New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review	published	6	2008	http://reports.ahta.at/763/
LTK adherence. Systematic review	published	7	2008	http://reports.ahta.at/784/
Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review	published	8	2008	http://reports.ahta.at/770/
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction in patients with congenital heart defects. Systematic review	published	10	2008	http://reports.ahta.at/768/
Selective Cell Adhesion in Inflammatory Bowel Disease	published	11	2008	http://reports.ahta.at/799/
Rheocheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review	published	12	2008	http://reports.ahta.at/768/
Optical Coherence Tomography. Systematic review	published	13	2008	http://reports.ahta.at/847/
Stem-cyrtins of the ascending aorta. Systematic review	published	14	2008	http://reports.ahta.at/780/
Cardiac contractility modulation for heart failure. Systematic review	published	15	2008	http://reports.ahta.at/769/
Aromatherapy for pain relief and psychological problems. Systematic review	published	16	2008	http://reports.ahta.at/765/
Bach Flower Remedies for pain relief and psychological problems. Systematic review	published	17	2008	http://reports.ahta.at/767/
Percutaneous aortic valve replacement. Systematic review	published	18	2008	http://reports.ahta.at/769/
Enzyme Replacement Therapy for Lysosomal Storage Diseases	published	19	2008	http://reports.ahta.at/812/
Endobronchial valve implantation for emphysema	finished	20	2008	not published

Title	Status	No.	Year	DownloadLink
Chemoneurolysis and intradiscal electrotherapy (IDET). Systematic Review	published	21a	2009	http://reports.ahta.at/828/
Percutaneous nucleotomy and percutaneous laser disk decompression. Systematic Review	published	21b	2009	http://reports.ahta.at/830/
Injection therapies and radiofrequency for the treatment of chronic back pain. Systematic Review	published	22	2009	http://reports.ahta.at/831/
Intraoperative radiotherapy for primary breast cancer. Systematic Review	published	23	2009	http://reports.ahta.at/832/
Drug coated balloon catheter. Systematic Review	published	24	2009	http://reports.ahta.at/833/
Selective IgG Apheresis for ABO-incompatible kidney transplantation. Systematic Review	published	25	2009	http://reports.ahta.at/834/
Image guided radiotherapy using cone-beam computed tomography. Systematic Review	published	26	2009	http://reports.ahta.at/835/
Pumpless extracorporeal lung assist (PECLA). Systematic Review	published	27	2009	http://reports.ahta.at/836/
Retroluminal transaperturary resection steno for the treatment of stress urinary incontinence in men. Systematic Review	published	30	2009	http://reports.ahta.at/837/
Stent-grafting of the ascending aorta. Systematic review	published	14/Update 2009	2009	http://reports.ahta.at/838/
Cardiac contractility modulation for heart failure. Systematic review	published	15/Update 2009	2009	http://reports.ahta.at/839/
Percutaneous aortic valve replacement. Systematic review	published	18/Update 2009	2009	http://reports.ahta.at/8397/
Endobronchial valve implantation for emphysema. Systematic review	finished	20/Update 2009	2009	not published
Bioresonance for allergies, atopic dermatitis, non-organic gastrointestinal complaints, pain and rheumatic diseases.	published	31	2009	http://reports.ahta.at/842/
Colon hydrotherapy for defecation disorders. Systematic Review	published	32	2009	http://reports.ahta.at/827/
International comparison of antenatal care in pregnant women	published	33	2009	http://reports.ahta.at/826/
Autologous Chondrocyte Implantation	published	34	2009	http://reports.ahta.at/865/
New influenza (swine flu) – data & facts for decision support	published	35	2009	http://reports.ahta.at/845/
Hyperthermia	published	36	2010	http://reports.ahta.at/853/
High intensity focused ultrasound (HIFU) for the treatment of prostate cancer	published	37	2010	http://reports.ahta.at/857/
Artificial disc replacement	published	38	2010	http://reports.ahta.at/856/
Laser angioplasty of coronary arteries	published	39	2010	http://reports.ahta.at/855/
Radioside therapy - 90Yttrium and 177Lu-dotatim - somatostatin analogues for the treatment of inoperable neuroendocrine tumors	published	40	2010	http://reports.ahta.at/858/
Mitral valve repair using a mitral clip	published	41	2010	http://reports.ahta.at/858/
Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review	published	8/ Update 2010	2010	http://reports.ahta.at/890/
Stent-grafting of the ascending aorta. Systematic review	published	14/ Update 2010	2010	http://reports.ahta.at/892/
Cardiac contractility modulation for heart failure. Systematic review	published	15/ Update 2010	2010	http://reports.ahta.at/893/
Percutaneous aortic valve replacement. Systematic review	published	18/ Update 2010	2010	http://reports.ahta.at/894/
Endobronchial valve implantation for emphysema. Systematic review	published	20/ Update 2010	2010	http://reports.ahta.at/891/
Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. German version	published	43	2011	http://reports.ahta.at/916/
Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. English version	published	43	2011	http://reports.ahta.at/917/
Percutaneous Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation	published	44	2011	http://reports.ahta.at/918/
Renal denervation in patients with essential hypertension	published	45	2011	http://reports.ahta.at/919/
Mechanical percutaneous transluminal cerebral revascularization in acute ischemic stroke	published	46	2011	http://reports.ahta.at/920/
Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. German version	published	47	2011	http://reports.ahta.at/921/
Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. English version	published	47	2011	http://reports.ahta.at/922/
Percutaneous aortic valve replacement with a side note to hybrid operating rooms	published	18/ Update 2011	2011	http://reports.ahta.at/923/
Outpatient cardiac rehabilitation. Part 4: Options for carrying out a prospective study	published	48	2011	http://reports.ahta.at/928/
Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases	published	49	2011	http://reports.ahta.at/933/
Outpatient cardiac rehabilitation. Part 5: Preparation of the study protocol for the planned prospective study	published	50	2012	http://reports.ahta.at/921/
Training therapy in physical medicine – Systematic Review	published	51	2012	http://reports.ahta.at/950/
Exercise therapy (Kräuterkymnastik/ Heilgymnastik) in physical medicine	published	52	2012	http://reports.ahta.at/951/
Radiofrequency ablation of tumors of the lung and mediastinal lymph nodes	published	53	2012	http://reports.ahta.at/957/
Radiofrequency ablation of bone tumors (osteoid-osteoma and osseous metastases)	published	54	2012	http://reports.ahta.at/958/
Radiofrequency ablation of head and neck cancer	published	55	2012	http://reports.ahta.at/959/
Radiofrequency ablation of benign and malignant nodules of endocrine organs (thyroid gland and adrenal gland)	published	56	2012	http://reports.ahta.at/960/
Radiofrequency ablation of breast cancer	published	57	2012	http://reports.ahta.at/961/
Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)	published	58	2012	http://reports.ahta.at/962/

Title	Status	No.	Year	DownloadLink
Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)	published	59	2012	http://reports.ahta.at/963/
Sling suspension in male urinary incontinence	published	60	2012	http://reports.ahta.at/964/
Stem cell therapy for urinary stress incontinence	published	61/Update 2012	2012	http://reports.ahta.at/965/
Mitral valve repair using a mitral clip	published	61/Update 2012	2012	http://reports.ahta.at/967/
Intraoperative radiotherapy for primary breast cancer, Systematic Review	published	231/Update 2012	2012	http://reports.ahta.at/969/
Renal denervation in patients with essential hypertension	published	45/Update 2012	2012	http://reports.ahta.at/968/
HIV testing in healthy subjects: an international comparison Austria	published	61	2012	http://reports.ahta.at/973/
Extracorporeal shock wave therapy (ESWT) of non-union or delayed union of fractures	published	62	2012	http://reports.ahta.at/975/
Hypertension	published	36/Update 2012	2012	http://reports.ahta.at/966/
Evidence overview of therapeutic hypothermia	published	63	2012	http://reports.ahta.at/964/
Percutaneous coronary intervention for chronic total occlusion	published	64	2013	http://reports.ahta.at/1000/
Implantation of a lumbar artificial endoprosthesis (artificial disc/ anular repair device)	published	65	2013	http://reports.ahta.at/1001/
Repair of cardiac defects via matrix-associated autologous chondrocyte implantation	published	66	2013	http://reports.ahta.at/1002/
Duodenal bypass liner (DUBL) for patients with obesity	published	67	2013	http://reports.ahta.at/1003/
Percutaneous transluminal angioplasty (PTA) of peripheral arteries with drug-eluting balloon (DEB)	published	68	2013	http://reports.ahta.at/1003/
Endovascular repair of aortic aneurysms	published	69	2013	http://reports.ahta.at/1004/
Percutaneous transcatheter closure of mitral and aortic paravalvular leaks	published	70	2013	http://reports.ahta.at/1005/
Percutaneous transluminal septal myocardial ablation (PTSA) in hypertrophic obstructive cardiomyopathy (HOCM)	published	71	2013	http://reports.ahta.at/1005/
Percutaneous transluminal coronary angioplasty (PTCA) with caclaxel-coated drug-eluting balloon (DEB) (1st Update)	published	24/Update 2013	2013	http://reports.ahta.at/1007/
Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations	published	72	2014	http://reports.ahta.at/1038/
Zostavax® for prevention of Herpes Zoster	published	73	2013	http://reports.ahta.at/1013/
Hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinoma	published	74	2014	http://reports.ahta.at/1031/
Percutaneous transluminal angioplasty (PTA) with drug-eluting stents	published	75	2014	http://reports.ahta.at/1032/
Endobronchial valves in emphysema	published	20/Update 2014	2014	http://reports.ahta.at/1029/
Percutaneous left atrial appendage closure	published	44/Update 2014	2014	http://reports.ahta.at/1023/
Stereotactic Radiofrequency Ablation (SRFA) in hepatocellular carcinoma	published	76	2014	http://reports.ahta.at/1030/
Biomarker guidance	published	77	2014	http://reports.ahta.at/1041/
Re-orientation of the Austrian parent-child preventive care programme Part 10: further development of the mother-child-pass, Scientific support of the appraisal process	published	78	2014	http://reports.ahta.at/1039/
Vaccination against Human Papillomavirus (HPV), Decision Support for adolescent girls and women/ mothers	finished	79	2014	not published
Outpatient cardiac rehabilitation, Part 6a: Multi-centre, prospective cohort study with two control groups (with/without phase III), Baseline characteristics	finished	80	2014	not published
Fully bioresorbable scaffolds for coronary artery disease: Systematic Review	published	81	2015	http://reports.ahta.at/1060/
Transcatheter mitral valve-in-valve implantation (TMVVi)	published	82	2015	http://reports.ahta.at/1058/
Endovascular embolisation of intracranial aneurysms with Flow Diverter	published	83	2015	http://reports.ahta.at/1054/
Defibrillators for bradycardia-arrhythmia disease	published	84	2015	http://reports.ahta.at/1051/
Intracranial ring segments for keratoconus	published	85	2015	http://reports.ahta.at/1055/
Neurostimulation for cluster headache	published	86	2015	http://reports.ahta.at/1062/
Local infection therapy with bulking agents for faecal incontinence	published	87	2015	http://reports.ahta.at/1059/
Percutaneous left atrial appendage closure (2 Update 2015)	published	44/Update 2015	2015	http://reports.ahta.at/1059/
Percutaneous transluminal angioplasty (PTA) of peripheral arteries with drug-eluting balloon (DEB) (1 Update 2015)	published	68/Update 2015	2015	http://reports.ahta.at/1057/
Medion therapy in children: Evidence synthesis in 15 pediatric tumors	published	88	2015	http://reports.ahta.at/1049/
Biodegradable stents for the treatment of refractory or recurrent benign oesophageal Stenosis, German summary to EUnetHTA-report	published	89	2015	http://reports.ahta.at/1067/
Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices	published	90	2015	http://reports.ahta.at/1063/
HTA Strategy for Lithuania	published	90a	2015	http://reports.ahta.at/1064/
Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction: German summary to EUnetHTA-report	published	91	2015	http://reports.ahta.at/1073/
Outpatient neurological rehabilitation, oral abatement in stroke patients, Systematic evidence	published	92	2015	http://reports.ahta.at/1071/
Percutaneous mitral repair with chronic mitral insufficiency (Mitracap®, Carillon®, NeoChord DS1000), German Executive summary of the same EUnetHTA report	published	93	2015	http://reports.ahta.at/1075/
Mechanical thrombolysis in acute ischemic stroke, German Executive summary of the same report EUnetHTA	published	94	2016	http://reports.ahta.at/1081/
Screening, diagnostic testing and therapeutic indication for occupational therapy in children and adolescents with Developmental Coordination Disorder	published	96	2016	http://reports.ahta.at/1082/
Leadless pacemakers for right ventricle pacing	published	97	2016	http://reports.ahta.at/1084/

Title	Status	No.	Year	DownloadLink
Autologous matrix-induced chondrogenesis for cartilage repair	published	98	2016	http://eprints.ahha.at/1090/
Radiofrequency denervation for low back pain	published	99	2016	http://eprints.ahha.at/1090/
Hypoglossal nerve stimulation for obstructive sleep apnoea	published	100	2016	http://eprints.ahha.at/1097/
Magnetic esophageal lino for gastroesophageal reflux disease	published	101	2016	http://eprints.ahha.at/1096/
Percutaneous transluminal coronary angioplasty with drug-eluting balloon	published	24/Update 2016	2016	http://eprints.ahha.at/1030/
Herzstill C virus screening in hospitals	published	102	2016	http://eprints.ahha.at/1103/
Portable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac arrest	published	103	2016	http://eprints.ahha.at/1109/
Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)	published	104	2017	http://eprints.ahha.at/1128/
Prostate artery embolization for benign prostatic hyperplasia	published	105	2017	http://eprints.ahha.at/1118/
Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS	published	106	2017	http://eprints.ahha.at/1129/
Deepbrain transcranial magnetic stimulation for treatment-resistant major depression	published	107	2017	http://eprints.ahha.at/1130/
Radiofrequency ablation for metastatic spinal lesions	published	108	2017	http://eprints.ahha.at/1131/
Percutaneous disc volume reduction with focus on chemonucleolysis	published	21 /Update 2017	2017	http://eprints.ahha.at/1126/
Leadless pacemakers for right ventricle pacing	published	97/Update 2017	2017	http://eprints.ahha.at/1127/
Endobronchial valve implantation for emphysema	published	20/4 Update 2018	2018	http://eprints.ahha.at/1168/
High intensity focused ultrasound (HIFU) for the treatment of prostate cancer	published	37/1 Update 2018	2018	http://eprints.ahha.at/1167/
Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation	published	149/ Update 2018	2018	http://eprints.ahha.at/1169/
Subcutaneous implantable cardioverter defibrillator (ICD)	published	109	2018	http://eprints.ahha.at/1169/
Lymphovenous anastomoses in patients with primary and secondary lymphedema	published	110	2018	http://eprints.ahha.at/1170/
Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas	published	111	2018	http://eprints.ahha.at/1171/
Metical allograft transplantation	published	112	2018	http://eprints.ahha.at/1172/
Baroreceptor activation therapy for treatment-resistant hypertension	published	113	2018	http://eprints.ahha.at/1173/
External stimulation of the trigeminal nerve for the prevention and treatment of episodic and chronic migraine (Cefaly)	published	114	2018	http://eprints.ahha.at/1177/
Wearable cardioverter-defibrillator (WCD) therapy as prevention of sudden cardiac death in patients at risk - Update 2018	published	103/Update 2018	2018	http://eprints.ahha.at/1186/
Osteochondral Allograft Transplantation (knee or other joints)	published	115	2019	http://eprints.ahha.at/1204/
Allograft for anterior and posterior cruciate ligament reconstruction	published	116	2019	http://eprints.ahha.at/1205/
Human dermal allograft for reconstruction of rotator cuff tears	published	117	2019	http://eprints.ahha.at/1206/
Lix 177-labeled Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Metastatic Prostate Cancer	published	118	2019	http://eprints.ahha.at/1207/
Radiofrequency denervation for lumbar and cervical facet joint pain	published	99/Update 2019	2019	http://eprints.ahha.at/1202/
(Single-step) scaffold-based cartilage repair in the knee	published	98/Update 2019	2019	http://eprints.ahha.at/1201/
Implantation of a lumbar artificial endoprosthesis (anuloplasty/ anular repair device)	published	85/Update 2019	2019	http://eprints.ahha.at/1200/
Upper airway stimulation for moderate-to-severe sleep apnoea	published	100/Update 2019	2019	http://eprints.ahha.at/1203/
Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report	published	81/1 Update 2019	2019	http://eprints.ahha.at/1191/
Transcatheter and subcutaneous artery pressure-guided treatment of heart failure	published	119	2020	http://eprints.ahha.at/1254/
Ultrasound-guided transcatheter Radiofrequency ablation of Myoma	published	120	2020	http://eprints.ahha.at/1255/
Leadless Pacemakers for Right Ventricle Pacing	published	97/Update 2019	2020	http://eprints.ahha.at/1252/
Extracorporeal cytokine haemadsorption	published	106/Update 2019	2020	http://eprints.ahha.at/1253/
Percutaneous transvascular implantation of a coronary sinus constricting stent	published	121	2020	http://eprints.ahha.at/1256/
Radiofrequency-induced Intravascular Chemoembolization for Non-Muscle-Invasive Bladder Cancer	published	122	2020	http://eprints.ahha.at/1258/
Photodynamic therapy in prostate cancer with psaltiporfin (TCC441)	published	123	2020	http://eprints.ahha.at/1259/
recutaneous left ventricular assist devices: micro-axial flow pumps	published	124	2021	http://eprints.ahha.at/1323/
Lipoasuction for surgical therapy of lipedema	published	125	2021	http://eprints.ahha.at/1324/
Triphasic biomaterial for augmentation of the osteoporotic femoral neck	published	126	2021	http://eprints.ahha.at/1325/
Endoscopic oclation therapy in patients with gastroesophageal reflux disease (GERD)	published	127	2021	http://eprints.ahha.at/1326/
Allogeneic bone screw Shark Screw® in patients with haloaxial or scapulothoracic fractures/osteotomies	published	128	2021	http://eprints.ahha.at/1327/
Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia	published	129	2021	http://eprints.ahha.at/1328/
Implantation of Bifluka Agents for Faecal Incontinence (1st Update)	published	87/1 Update	2021	http://eprints.ahha.at/1322/
Percutaneous coronary interventions (PCI) for chronic total occlusion. Update 2022	published	64/Update 2022	2022	http://eprints.ahha.at/1388/

Title	Status	No.	Year	DownloadLink
Upper airway stimulation for moderate-to-severe sleep apnea. Update 2022	published	100/Update 2022	2022	https://reports.ahta.at/1387
Subcutaneous implantable cardioverter defibrillator (ICD)	published	109/Update 2022	2022	https://reports.ahta.at/1388
Pericardaneous Transvascular Implantation of a Coronary Sinus Reducing Stent	published	121/Update 2022	2022	https://reports.ahta.at/1389
Hevlic and acetic acid jet embolization prior to major hepatectomy	published	130	2022	https://reports.ahta.at/1390
Ultrasound-guided microwave ablation for liver tumours	published	131	2022	https://reports.ahta.at/1391
HIS Bundle Pacing for patients requiring permanent pacemaker	published	132	2022	https://reports.ahta.at/1392
Chemoradiation with percutaneous hepatic perfusions for patients with liver metastases	published	133	2022	https://reports.ahta.at/1393
Lower Esophageal Sphincter Devices for Laparoscopic Surgery in Patients with Gastroesophageal Reflux Disease (GERD): magnetic sphincter augmentation device (MSAD) (Update 101), electric stimulation therapy (update 104), Refluxion™ (new)	published	134	2022	https://reports.ahta.at/1394
Wearable cardioverter-defibrillator (WCD) therapy as prevention of sudden cardiac death in patients at risk – Update 2022	published	103/ Update 2022	2022	https://reports.ahta.at/1407
Pericardaneous aspiration thrombectomy for pulmonary embolism	published	135	2023	https://reports.ahta.at/1454
Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor	published	136	2023	https://reports.ahta.at/1455
Bicymycin Electrostimulation for Vascular Anomalies	published	137	2023	https://reports.ahta.at/1456
Electrical auticular vagus nerve stimulation for pain	published	138	2023	https://reports.ahta.at/1457
Pericardaneous mitral valve repair with a clip device in patients with mitral regurgitation	published	41/2 Update 2023	2023	https://reports.ahta.at/1451
Allogeneic mesenchymal stem cells for Crohn's Disease-associated colonic cryptitis fistulae	published	111/1 Update 2023	2023	https://reports.ahta.at/1452
177Lu-PSMA-Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review	published	119/1 Update 2023	2023	https://reports.ahta.at/1453
Carotid valve implantation for severe tricuspid regurgitation	ongoing	139	2024	https://reports.ahta.at/1525
Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia	ongoing	140	2024	https://reports.ahta.at/1526
Thermocoagulation for benign thyroid nodules	ongoing	141	2024	https://reports.ahta.at/1527
Pericardaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD)	ongoing	24/3 Update 2024	2024	https://reports.ahta.at/1528
Renal denervation (RDN) in patients with treatment-resistant hypertension	ongoing	142/ Update 2024	2024	https://reports.ahta.at/1529
Islet cell transplantation for pancreatocellular, type 1 diabetes with severe hypoglycemia, and after kidney transplantation	ongoing	143	2025	https://reports.ahta.at/1564
Drug-coated balloon catheter for treatment of urethral strictures	ongoing	144	2025	https://reports.ahta.at/1565
Thermocoagulation as primary or adjuvantive therapy for breast cancer	ongoing	145	2025	https://reports.ahta.at/1566
One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee	ongoing	146	2025	https://reports.ahta.at/1567
Leadless pacemakers for right ventricle pacing. 3 Update 2025	ongoing	87/3 Update 2024	2025	https://reports.ahta.at/1568
Temporary radial implantation for the treatment of benign prostatic hyperplasia	ongoing	129/1 Update 2024	2025	https://reports.ahta.at/1569
Decision Support Documents - Horizon Scanning in Oncology				
Azaxidine (Vidaza®) for the treatment of myelodysplastic syndromes	published	1	2009	http://reports.ahta.at/852/
Cetuximab (Erbixub®) in EGFR-expressing Non-Small Cell Lung Cancer	published	2	2009	http://reports.ahta.at/856/
Everolimus (Afinitor®) for advanced/metastatic kidney cancer	published	3	2009	http://reports.ahta.at/857/
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia	published	4	2009	http://reports.ahta.at/860/
Polatumumab (Hu5d9) as consolidation therapy after first remission in patients with follicular lymphoma	published	5	2009	http://reports.ahta.at/861/
Defolitin (Iressa®) for the first-line treatment of non-small cell lung cancer	published	6	2010	http://reports.ahta.at/869/
Trastuzumab (Herceptin®) for second-line recurrent platinum-sensitive ovarian cancer	published	7	2010	http://reports.ahta.at/869/
Plerixafor (Mozobil®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma	published	8	2010	http://reports.ahta.at/878/
Lapatinib dihydroate (Tyverb®/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer	published	9	2010	http://reports.ahta.at/882/
Benclumastine (Ribomustin®/Treatdalf®/Leved®) for indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma	published	10	2010	http://reports.ahta.at/884/
Panitumumab (Vectibiv®) for the first-line treatment of metastatic colorectal cancer	published	11	2010	http://reports.ahta.at/888/
Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer	published	12	2010	http://reports.ahta.at/881/
Pazopanib (Votivo®) for the treatment of locally advanced and/or metastatic renal cell carcinoma	published	13	2010	http://reports.ahta.at/902/
Pilipinimab for pre-treated patients with advanced/metastatic melanoma	published	14	2011	http://reports.ahta.at/905/
Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase	published	15	2011	http://reports.ahta.at/906/
Cabazitaxel (Jevtana®) for the second-line therapy of patients with hormone-refractory metastatic prostate cancer	published	16	2011	http://reports.ahta.at/911/
Dasatinib (Sprycel®) for the first-line therapy of patients with newly diagnosed chronic phase Philadelphia chromosome positive chronic myeloid leukemia	published	17	2011	http://reports.ahta.at/910/
Eribulin (Halaven®) as third- or late-line mono-therapy for advanced/metastatic breast cancer	published	18	2011	http://reports.ahta.at/927/
ES-1 (Tessaro) in chemotherapy-naïve patients with advanced NSCLC	published	19	2011	http://reports.ahta.at/931/
Abliraterone acetate (ZoviyTM) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy	published	20	2011	http://reports.ahta.at/938/

Title	Status	No.	Year	DownloadLink
Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011	published	6/ Update 2011	2011	http://reports.ahha.at/936/
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia – 1st Update 2011	published	4/ Update 2011	2011	http://reports.ahha.at/937/
Panitumumab (Vectibix®) as 1st line combination therapy for the treatment of WT KRAS metastatic colorectal cancer – 1st Update 2011	published	11/ Update 2011	2011	http://reports.ahha.at/939/
Axitinib for 2nd-line metastatic renal cell carcinoma	published	21	2012	http://reports.ahha.at/944/
Gefitinib for the 1st-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations	published	22	2012	http://reports.ahha.at/941/
Vemurafenib for the 1st-line unresectable stage IIIc or IV melanoma	published	23	2012	http://reports.ahha.at/940/
Everolimus for advanced pancreatic neuroendocrine tumours	published	24	2012	http://reports.ahha.at/942/
Romidepsin for the treatment of peripheral T-cell lymphoma	published	25	2012	http://reports.ahha.at/956/
Brentuximab vedotin for the treatment of Hodgkin Lymphoma and systemic anaplastic large cell lymphoma	published	26	2012	http://reports.ahha.at/955/
Bevacizumab in combination with chemotherapy regimens for previously treated HER2-negative metastatic breast cancer	published	27	2012	http://reports.ahha.at/952/
Lenalidomide for the treatment of myelodysplastic syndromes	published	28	2012	http://reports.ahha.at/954/
Bortezomib for the treatment of multiple myeloma in a transplant setting	published	29	2012	http://reports.ahha.at/970/
Ipilimumab for the first-line therapy of advanced/metastatic melanoma	published	30	2012	http://reports.ahha.at/970/
Perituzumab for the first-line therapy of metastatic HER2-positive breast cancer	published	31	2012	http://reports.ahha.at/978/
Everolimus for the treatment of breast cancer	published	32	2012	http://reports.ahha.at/977/
Lenalidomide for the first-line therapy of multiple myeloma	published	33	2012	http://reports.ahha.at/964/
Trametinib for advanced or metastatic BRAF V600E mutation-positive melanoma	published	34	2012	http://reports.ahha.at/968/
Copanil (PF-0121096) (Paliperidone) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)	published	35	2012	http://reports.ahha.at/959/
Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer	published	36	2013	http://reports.ahha.at/998/
Enzalutamide (Xtandi®) for patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy	published	37	2013	http://reports.ahha.at/997/
Aflibercept (Zaltrap®) in addition to FOLFIRI for the treatment of metastatic colorectal cancer	published	38	2013	http://reports.ahha.at/999/
Pomalidomide (Pomalyst®) in combination with low-dose dexamethasone vs. high-dose dexamethasone in subjects with refractory multiple myeloma or relapsed and refractory multiple myeloma	published	39	2013	http://reports.ahha.at/1010/
Resoratinib (BHW669) in pts with metastatic colorectal cancer (CRC) who have progressed after standard therapy	published	40	2013	http://reports.ahha.at/1011/
Afinib (Egfrin®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations	published	41	2013	http://reports.ahha.at/1002/
Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage IIIb) or metastatic (stage IV) melanoma	published	42	2013	http://reports.ahha.at/1015/
Nab-Paclitaxel (Abraxane®/Eltaxel®) as first-line therapy for metastatic adenocarcinoma of the pancreas	published	43	2014	http://reports.ahha.at/1023/
Radium-223 Dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease	published	44	2014	http://reports.ahha.at/1024/
Obinutuzumab afiluzumab (Gazyva®) as first line therapy for chronic lymphocytic leukaemia (CLL)	published	45	2014	http://reports.ahha.at/1027/
Bevacizumab (Avastin®) as maintenance therapy for patients with advanced colorectal carcinoma	published	46	2014	http://reports.ahha.at/1034/
Erdotinib (PC-32765 (Imbruvic®)) for relapsed or refractory CLL	published	47	2014	http://reports.ahha.at/1037/
Bevacizumab (Avastin®) for relapsed-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer	published	48	2014	http://reports.ahha.at/1039/
Vedolizumab (Zelmac®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia	published	49	2014	http://reports.ahha.at/1044/
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma	published	50	2015	http://reports.ahha.at/1061/
Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy	published	51	2015	http://reports.ahha.at/1066/
Carfilzomib (Kyprolis®) in patients with relapsed multiple myeloma who have received one to three prior lines of therapy	published	52	2015	http://reports.ahha.at/1070/
Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer	published	53	2015	http://reports.ahha.at/1068/
Pembrolizumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma	published	54	2015	http://reports.ahha.at/1069/
Pembrolizumab (Keytruda®) for the treatment of advanced melanoma	published	55	2015	http://reports.ahha.at/1079/
Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer	published	56	2016	http://reports.ahha.at/1082/
Opavumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)	published	57	2016	http://reports.ahha.at/1085/
Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)	published	58	2016	http://reports.ahha.at/1088/
Afinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy	published	59	2016	http://reports.ahha.at/1089/
Obinutuzumab (Gazyva®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)	published	60	2016	http://reports.ahha.at/1102/
Alectinib (Tasigna™) for the treatment of locally advanced and metastatic urothelial carcinoma	published	61	2016	http://reports.ahha.at/1104/
Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion	published	62	2016	http://reports.ahha.at/1105/
Ipazomicin (Nintao™) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)	published	63	2016	http://reports.ahha.at/1111/
Palbocicli (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer	published	64	2017	http://reports.ahha.at/1114/

Title	Status	No.	Year	DownloadLink
Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer	published	65	2017	http://reports.altix.at/1116/
Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy	published	66	2017	http://reports.altix.at/1116/
Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma	published	67	2017	http://reports.altix.at/1119/
Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)	published	68	2017	http://reports.altix.at/1120/
Carboplatin (Cisplatin®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer	published	69	2017	http://reports.altix.at/1123/
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)	published	70	2017	http://reports.altix.at/1124/
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer	published	71	2017	http://reports.altix.at/1130/
Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)	published	72	2017	http://reports.altix.at/1137/
Receptor tyrosine kinase inhibitors as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib, EUnetHTA report	published	73	2017	http://reports.altix.at/1138/
Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukemia	published	74	2017	http://reports.altix.at/1140/
Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)	published	75	2017	http://reports.altix.at/1144/
Durvalumab (Imfinzi™) for the treatment of patients with stage II non-small-cell lung cancer after prior chemotherapy	published	76	2017	http://reports.altix.at/1145/
Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)	published	77	2018	http://reports.altix.at/1150/
Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)	published	78	2018	http://reports.altix.at/1154/
Rituximab (Mab Thera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)	published	79	2018	http://reports.altix.at/1155/
Oestrone (Etoposin®) for the initial treatment of ECR-mutated advanced non-small-cell lung cancer (NSCLC)	published	80	2018	http://reports.altix.at/1160/
Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma	published	81	2018	http://reports.altix.at/1161/
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC	published	82	2018	http://reports.altix.at/1175/
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)	published	83	2018	http://reports.altix.at/1176/
Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)	published	84	2018	http://reports.altix.at/1184/
brutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström's macroglobulinemia	published	85	2018	http://reports.altix.at/1185/
Olaparib (Lynparza®) für die Erstlinien-Erhaltungstherapie von Patientinnen mit neu diagnostiziertem, fortgeschrittenem Ovarialkarzinom	published	86	2019	http://reports.altix.at/1192/
Atezolizumab (Tecentriq®) und Nab-Paclitaxel (Abraxane®) für die Behandlung von Patientinnen mit fortgeschrittenem, triple-negativem Mammakarzinom (aTNBC)	published	87	2019	http://reports.altix.at/1193/
Daratumumab für die Behandlung von Patientinnen mit nichtrelapierendem, histioplasmatischem Plasmozytom	published	88	2019	http://reports.altix.at/1199/
Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)	published	89	2019	http://reports.altix.at/1210/
Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)	published	90	2019	http://reports.altix.at/1216/
Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)	published	91	2019	http://reports.altix.at/1219/
HTA Informationsdienst Rapid Reviews				
iv Immunoglobulin (IVIg) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss	published	1	2024	https://reports.altix.at/1434/
Extracorporeal shock wave therapy for orthopaedic indications	published	2	2024	https://reports.altix.at/1435/
Radiofrequency denervation for chronic lumbar or cervical spine pain	published	3	2024	https://reports.altix.at/1448/
Biomarkers in Alzheimer's Disease	published	4	2024	https://reports.altix.at/1471/
Robot-assisted rehabilitation for incomplete spinal cord injury	published	5	2024	https://reports.altix.at/1478/
Myopia control spectacle lenses for children and adolescents	published	6	2024	https://reports.altix.at/1489/
Autologous fat grafting in osteoarthritis	published	7	2024	https://reports.altix.at/1490/
Endovascular laser therapy for varicose veins in the lower extremities	published	8	2024	https://reports.altix.at/1490/
Liposuction for the removal of subcutaneous (fat) lipomas	published	9	2024	https://reports.altix.at/1498/
Biomarkers in Parkinson's Disease	published	10	2024	https://reports.altix.at/1500/
Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023	published	11	2024	https://reports.altix.at/1504/
Use of telepathology for intraoperative frozen section examination	published	12	2024	https://reports.altix.at/1505/
CAR-based immunotherapy with a focus on CAR-ANK cells	published	13	2024	https://reports.altix.at/1513/
Skin cancer prevention: Guideline recommendations for primary and secondary prevention	published	14	2024	https://reports.altix.at/1514/
Massive parallel sequencing – technologies for high-throughput analysis of genic-genomic data sets	published	15	2024	https://reports.altix.at/1536/
Reimbursement models and pricing of digital health technologies and telemonitoring applications	published	16	2025	https://reports.altix.at/1556/
Serum eye drops for patients with severe ocular surface disease	published	17	2025	https://reports.altix.at/1559/
Rehabilitation for Movement Support in People with Chronic Back Pain – Rapid Review of Effectiveness	published	18	2025	https://reports.altix.at/1561/
Erdotinib Vedotin in combination with Pembrolizumab in Urothelial Cancer	published	19	2025	https://reports.altix.at/1575/

Title	Status	No.	Year	DownloadLink
Decision Support Documents, Oncology Fact Sheets				
Venetoclax (Venclexta®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions	published	1	2020	http://reports.ahha.at/1229/
Darolutamide (Nubevo®) in nonmetastatic, castration-resistant prostate cancer (mCRPC)	published	2	2020	http://reports.ahha.at/1230/
Rituximab (MabThera®) for the treatment of caesitatic patients with previously untreated advanced stage CD20 positive DLBCL, BL, BA1, or BL2	published	3	2020	http://reports.ahha.at/1231/
Brintellinib (Aimovig®) in ALK-positive non-small-cell lung cancer (NSCLC)	published	4	2020	http://reports.ahha.at/1232/
Bravutinib vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)	published	5	2020	http://reports.ahha.at/1233/
Ibrutinib (Imbruvic®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)	published	6	2020	http://reports.ahha.at/1236/
Encorafenib (Braftor®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation	published	7	2020	http://reports.ahha.at/1240/
Cabozantinib (Cabotiv®) for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen	published	8	2020	http://reports.ahha.at/1241/
Daratumumab (Darzalex®) in a new chemoregimen associated with a new strength and a new route of administration for the treatment of multiple myeloma	published	9	2020	http://reports.ahha.at/1242/
Glasdegib (Daurigen®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)	published	10	2020	http://reports.ahha.at/1243/
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer	published	11	2020	http://reports.ahha.at/1246/
Alpelisib (Piquris®) plus fulvestrant for PIK3CA-mutated, hormone receptor-positive advanced breast cancer	published	12	2020	http://reports.ahha.at/1247/
Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC	published	13	2020	http://reports.ahha.at/1248/
Camptothecin (Camptogen®) as conditioning treatment before transplantation in patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphomas (NHL)	published	14	2020	http://reports.ahha.at/1261/
Acutelebinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)	published	15	2020	http://reports.ahha.at/1263/
Avapritinib (Avykat®) for the treatment of gastrointestinal stromal tumours (GIST)	published	16	2020	http://reports.ahha.at/1264/
Relatamab mafodotin (Relpevo®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)	published	17	2020	http://reports.ahha.at/1265/
Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	published	18	2020	http://reports.ahha.at/1266/
Eribulin (Eribulin®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)	published	19	2020	http://reports.ahha.at/1267/
Alemtuzumab (Lemtroni®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)	published	20	2020	http://reports.ahha.at/1270/
Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)	published	21	2020	http://reports.ahha.at/1271/
Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer	published	22	2020	http://reports.ahha.at/1272/
Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)	published	23	2020	http://reports.ahha.at/1273/
Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer	published	24	2020	http://reports.ahha.at/1274/
Rituximab (MabThera®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)	published	25	2020	http://reports.ahha.at/1276/
Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (ES/SCC)	published	26	2020	http://reports.ahha.at/1277/
Autogossu anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)	published	27	2020	http://reports.ahha.at/1278/
Tagraxofusp (Elzonvid®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)	published	28	2020	http://reports.ahha.at/1284/
Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)	published	29	2020	http://reports.ahha.at/1285/
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zinc (Phesgo™) for the treatment of early and metastatic breast cancer	published	30	2020	http://reports.ahha.at/1286/
Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma	published	31	2020	http://reports.ahha.at/1287/
Trastuzumab desitumab (Enhertu®) in patients with previously treated HER2-positive breast cancer	published	32	2021	http://reports.ahha.at/1288/
Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis	published	33	2020	http://reports.ahha.at/1289/
Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI-H or dMMR colorectal cancer	published	34	2021	http://reports.ahha.at/1290/
Moaxlutumab pasodotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)	published	35	2021	http://reports.ahha.at/1291/
Selpercatinib (Retevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary thyroid cancer	published	36	2021	http://reports.ahha.at/1292/
Tucatinib (Tucvasa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer	published	37	2021	http://reports.ahha.at/1293/
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)	published	38	2021	http://reports.ahha.at/1296/
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)	published	39	2021	http://reports.ahha.at/1297/
Pemparitinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement	published	40	2021	http://reports.ahha.at/1298/
Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)	published	41	2021	http://reports.ahha.at/1299/
Nivolumab (Opdivo®) in combination with cabozantinib (Cabomety®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)	published	42	2021	http://reports.ahha.at/1300/
Ibrutinib (Imbruvic®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)	published	43	2021	http://reports.ahha.at/1301/
Davlatinib (Cosbuvic®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)	published	44	2021	http://reports.ahha.at/1304/
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)	published	45	2021	http://reports.ahha.at/1305/
Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)	published	46	2021	http://reports.ahha.at/1306/
Azasulidine (Onurep®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)	published	47	2021	http://reports.ahha.at/1309/
Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIa non-small cell lung cancer (NSCLC)	published	48	2021	http://reports.ahha.at/1310/

Title	Status	No.	Year	DownloadLink
Venetoclax (Venclyxt®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)	published	49	2021	https://reports.ahit.at/1311/
Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)	published	52	2021	https://reports.ahit.at/1316/
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer	published	51	2020	https://reports.ahit.at/1315/
Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)	published	52	2020	https://reports.ahit.at/1316/
Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (BCC or mBCC)	published	53	2021	https://reports.ahit.at/1317/
Pembrolizumab (Keytruda®) in combination with platinum and fluorouracil based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the esophagus	published	54	2021	https://reports.ahit.at/1318/
Daratumumab (Darzalex®) in combination with romalidomide and dexamethasone for the treatment of multiple myeloma (MM)	published	55	2021	https://reports.ahit.at/1319/
Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis	published	56	2021	https://reports.ahit.at/1320/
Mecablagene vicleucel (Abecma®) for the treatment of patients with relapsed or refractory multiple myeloma (MM)	published	57	2021	https://reports.ahit.at/1330/
Tafasitamab (Munya®; Monjuva®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	published	58	2021	https://reports.ahit.at/1331/
Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC)	published	59	2021	https://reports.ahit.at/1332/
Ipilimumab (Yervoy®) as monotherapy for the treatment of patients with wild-type metastatic melanoma (MM)	published	60	2021	https://reports.ahit.at/1336/
Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)	published	61	2021	https://reports.ahit.at/1337/
Ripretinib (Qinlar®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)	published	62	2021	https://reports.ahit.at/1338/
oesophageal adenocarcinoma	published	63	2021	https://reports.ahit.at/1339/
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)	published	64	2021	https://reports.ahit.at/1340/
Pembrolizumab (Keytruda®) in combination with Lenvatinib (Lenvima®) for the first-line treatment of advanced renal cell carcinoma (RCC)	published	67	2021	https://reports.ahit.at/1343/
Pembrolizumab (Keytruda®) in combination with Lenvatinib (Lenvima®) for the treatment of advanced or recurrent endometrial carcinoma (EC)	published	68	2021	https://reports.ahit.at/1344/
Amlutamab (Bybreve®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)	published	69	2021	https://reports.ahit.at/1345/
Sacituzumab govitecan (Trodelvy®) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)	published	70	2021	https://reports.ahit.at/1346/
Sotorasib (Lumvkras®; Sotorasib (Lumvkras®)) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation	published	71	2021	https://reports.ahit.at/1347/
Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer	published	72	2022	https://reports.ahit.at/1353/
Tecovitin (Tecovitin®) as monotherapy for the treatment of patients with advanced renal cell cancer (NSCLC)	published	73	2022	https://reports.ahit.at/1354/
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC)	published	74	2022	https://reports.ahit.at/1355/
Lorlatinib (Lorlatinib®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)	published	75	2022	https://reports.ahit.at/1356/
Tafariguimeraciloteracel (Teyvoni®) for the treatment of metastatic colorectal cancer	published	76	2022	https://reports.ahit.at/1357/
Lisocabtagene maraleucel (Breyanzi®) for the treatment of relapsed or refractory DLBCL	published	77	2022	https://reports.ahit.at/1359/
Avapritinib (Avapritinib®) for the treatment of advanced systemic mastocytosis (ADM)	published	78	2022	https://reports.ahit.at/1360/
Tecovitin (Tecovitin®) bei Urothelkarzinomen	published	79	2022	https://reports.ahit.at/1361/
Relatovir (Opovov®) bei Prostata Cancer	published	80	2022	https://reports.ahit.at/1362/
Nivolumab (Opdivo®) bei MSI-C	published	81	2022	https://reports.ahit.at/1363/
Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC	published	82	2022	https://reports.ahit.at/1364/
Nivolumab (Opdivo®) + chemotherapy bei OSCC	published	83	2022	https://reports.ahit.at/1365/
Atenackitin (Vzerenios®) bei early breast cancer	published	84	2022	https://reports.ahit.at/1366/
Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer	published	85	2022	https://reports.ahit.at/1367/
Cituxetanogene autalucel (Cytuxetra®) for the treatment of multiple myeloma (MM)	published	86	2022	https://reports.ahit.at/1371/
Cabozantinib (Cabomety®) as monotherapy for the treatment of thyroid carcinoma (DTC)	published	87	2022	https://reports.ahit.at/1372/
Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy	published	88	2022	https://reports.ahit.at/1373/
Pofavuzumab vedotin (Pofivodi®) in combination with rhuximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)	published	89	2022	https://reports.ahit.at/1374/
Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer	published	90	2022	https://reports.ahit.at/1375/
Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer	published	91	2022	https://reports.ahit.at/1376/
Mosunessumab (Lumsonni®) Follicular lymphoma	published	92	2022	https://reports.ahit.at/1377/
Capmatinib (Tabrecta®) NSCLC	published	93	2022	https://reports.ahit.at/1378/
Pembrolizumab (Keytruda®) TNBC	published	94	2022	https://reports.ahit.at/1379/
Relatovir (Opovov®) NSCLC	published	95	2022	https://reports.ahit.at/1380/
Atezolizumab (Tecentriq®) NSCLC	published	96	2022	https://reports.ahit.at/1381/
Axicabtanene cilucel (Yescarta®) Follicular lymphoma	published	97	2022	https://reports.ahit.at/1382/

Title	Status	No.	Year	DownloadLink
Selinexor (Nesopio®) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma (MM)	published	98	2022	https://eprints.ohfa.at/1384/
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection	published	99	2022	https://eprints.ohfa.at/1385/
Melphalan flufenamide (Pezavis®) with dexamethasone for the treatment of multiple myeloma (MM)	published	100	2022	https://eprints.ohfa.at/1395/
Aspirin (Gemirol®) for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CM) in chronic phase (CP)	published	101	2022	https://eprints.ohfa.at/1396/
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2-positive breast cancer	published	102	2022	https://eprints.ohfa.at/1397/
brutinib (Imbruvic®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)	published	103	2022	https://eprints.ohfa.at/1398/
Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer	published	104	2022	https://eprints.ohfa.at/1399/
Retelimumab/hivolumab (Ocularis®) for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%	published	105	2022	https://eprints.ohfa.at/1400/
Autologous anti-CD19-transduced CD34+ cells (Tecartus®) for the treatment of adult patients 20 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)	published	106	2022	https://eprints.ohfa.at/1404/
Tecolitamab (Tecoviv®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies	published	107	2022	https://eprints.ohfa.at/1405/
Relatlimab (Relivry®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)	published	108	2022	https://eprints.ohfa.at/1406/
Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)	published	109	2022	https://eprints.ohfa.at/1409/
Zincfinger nucleases (Zincfinger®) as monotherapy for the treatment of marginal zone lymphoma (MZL)	published	110	2022	https://eprints.ohfa.at/1410/
Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)	published	111	2022	https://eprints.ohfa.at/1411/
Zincfinger nucleases (Zincfinger®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)	published	112	2022	https://eprints.ohfa.at/1412/
Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer	published	113	2022	https://eprints.ohfa.at/1413/
Luteolum (17 Lu) vipivoxole tetaxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	published	114	2022	https://eprints.ohfa.at/1414/
Trastuzumab deruxtecan (Enhertu®) for Gastric or gastroesophageal junction (GEJ) adenocarcinoma	published	115	2022	https://eprints.ohfa.at/1421/
Durvalumab (Imfinzi®) for Biliary tract cancer	published	116	2022	https://eprints.ohfa.at/1422/
Olaparib (Lynparza®) for mCRPC	published	117	2023	https://eprints.ohfa.at/1424/
Tremelimumab (Imfinzi®) + Durvalumab (Imfinzi®) for HCC	published	118	2023	https://eprints.ohfa.at/1425/
Tremelimumab (Tremelimumab AdoZene®) + Durvalumab (Imfinzi®) + Chemotherapy for NSCLC	published	119	2023	https://eprints.ohfa.at/1426/
Trastuzumab deruxtecan (Enhertu®) for HER2-low breast cancer	published	120	2023	https://eprints.ohfa.at/1427/
Nadofarolan Firdaronec (Adstallin®) for Bladder cancer	published	121	2023	https://eprints.ohfa.at/1429/
Doptuzumab monatox (Vicinum®) for Bladder cancer	published	122	2023	
Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)	published	123	2023	https://eprints.ohfa.at/1429/
Clopidogridesic acid (Pembib®) in combination with Mirustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase (GAA) deficiency)	published	124	2023	https://eprints.ohfa.at/1430/
Niraparin/valproic acid (Akeveo®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	published	125	2023	https://eprints.ohfa.at/1432/
Isosertib (Tibosert®) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML)	published	126	2023	https://eprints.ohfa.at/1433/
Isosertib (Tibosert®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma	published	127	2023	https://eprints.ohfa.at/1439/
Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)	published	128	2023	https://eprints.ohfa.at/1439/
Lincocicogene marautecel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update Jul. 2023	published	129	2023	https://eprints.ohfa.at/1440/
Glofitamab (Colum®) as monotherapy for the treatment of relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL)	published	130	2023	https://eprints.ohfa.at/1441/
Pirtrotinib (Layvica™) as monotherapy for the treatment of relapsed or refractory (RR) mantle cell lymphoma (MCL)	published	131	2023	https://eprints.ohfa.at/1444/
Fulvestrant (Tasoc®) for the treatment of locally advanced or metastatic cholangiocarcinoma	published	132	2023	https://eprints.ohfa.at/1445/
Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC)	published	133	2023	https://eprints.ohfa.at/1446/
Piflufolastat (HF1) (Pylclar®) for the diagnosis of prostate cancer	published	134	2023	https://eprints.ohfa.at/1447/
Tremelimumab (Imfinzi®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)	published	135	2023	https://eprints.ohfa.at/1449/
Tiflutidine / lipiracil (Lonsar®_TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC)	published	136	2023	https://eprints.ohfa.at/1450/
Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone-receptor-negative, HER2-negative breast cancer	published	137	2023	https://eprints.ohfa.at/1458/
Orinostatone (Erandar®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (BL)	published	138	2023	https://eprints.ohfa.at/1459/
Cedazuridone/decitabine (Inoqovo®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)	published	139	2023	https://eprints.ohfa.at/1460/
Elacestrat (Qesdrol®) monotherapy for the treatment of oestrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer	published	140	2023	https://eprints.ohfa.at/1462/
Talquetamab (Taktevy®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)	published	141	2023	https://eprints.ohfa.at/1463/
Epcoritamab (Teeviki®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	published	142	2023	https://eprints.ohfa.at/1464/
Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC)	published	143	2023	https://eprints.ohfa.at/1465/

Title	Status	No.	Year	DownloadLink
Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage III or IV melanoma, or melanoma with involvement of lymph nodes or metastatic disease	published	144	2023	https://reports.altix.at/1466/
Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma	published	145	2023	https://reports.altix.at/1467/
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation	published	147	2023	https://reports.altix.at/1468/
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC)	published	148	2023	https://reports.altix.at/1469/
Mechthildifenemide (Pevonia) in combination with desmethylazetidine for the treatment of multiple myeloma (MM)	published	149	2023	https://reports.altix.at/1470/
Quazartinib (Vantictum®) in combination with standard cytarabine and arabinoside induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML)	published	150	2023	https://reports.altix.at/1473/
Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL)	published	151	2023	https://reports.altix.at/1474/
Erlotinamab (Erlotinib®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM)	published	152	2023	https://reports.altix.at/1475/
Durvalumab (Imfinzi®) as monotherapy for the first-line treatment of advanced or unresectable hepatocellular carcinoma (HCC)	published	153	2023	https://reports.altix.at/1476/
Capripitumab (Capripit®) with carboplatin and paclitaxel for the treatment of mismatch repair-deficient (dMMR) microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC)	published	154	2023	https://reports.altix.at/1478/
Adisiranib (Kivara®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC)	published	155	2023	https://reports.altix.at/1480/
Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer	published	156	2023	https://reports.altix.at/1481/
Avapritinib (Avayvit®) for the treatment of indolent systemic mastocytosis (ISM)	published	157	2023	https://reports.altix.at/1482/
Pembrolizumab (Keytruda®) with omechabine and capecitabine for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC)	published	158	2023	https://reports.altix.at/1483/
Adisiranib (Kivara®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC)	published	159	2023	https://reports.altix.at/1484/
post-essential thrombocythemia myelofibrosis	published	160	2023	https://reports.altix.at/1491/
Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	published	161	2023	https://reports.altix.at/1492/
Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies	published	162	2024	https://reports.altix.at/1493/
Selexiparin (Relexivo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RCT fusion-positive thyroid cancer	published	163	2024	https://reports.altix.at/1494/
Tislelizumab (Tisleori®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)	published	164	2024	https://reports.altix.at/1495/
Beiferenimab (Zynvivo®) as monotherapy for the first-line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma	published	165	2024	https://reports.altix.at/1500/
Clilranabactam subcutaneous (Cayvakt®) for the treatment of relapsed and refractory multiple myeloma (MM)	published	166	2024	https://reports.altix.at/1506/
Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non-small cell lung carcinoma (NSCLC)	published	167	2024	https://reports.altix.at/1508/
Imnovid (hydrocortisone 17-butyrate (Cytelact®) population (iposonil) in combination with cisplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas	published	168	2024	https://reports.altix.at/1510/
Selexiparin (Relexivo®) as monotherapy for the treatment of advanced rearranged duplo transfection (RET) fusion-positive solid tumours	published	169	2024	https://reports.altix.at/1511/
Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high-risk biochemical recurrence (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)	published	170	2024	https://reports.altix.at/1512/
Frustrumab (Frustrum®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)	published	171	2024	https://reports.altix.at/1515/
Capivasertib (Tropid®) with fulvestrant for the treatment ER-positive, HER2-negative locally advanced or metastatic breast cancer	published	172	2024	https://reports.altix.at/1516/
Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC)	published	173	2024	https://reports.altix.at/1517/
Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma	published	174	2024	https://reports.altix.at/1518/
Entrectinib (Rozlyvy®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion	published	175	2024	https://reports.altix.at/1519/
Amivantamab (Rybrevant®) with carboplatin and pemterved for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations	published	176	2024	https://reports.altix.at/1520/
Supernemab (Coemivy®) with platinum-based chemotherapy for the first-line treatment of metastatic non-small-cell lung cancer (NSCLC)	published	177	2024	https://reports.altix.at/1521/
Osimertinib (Tagrisso®) with pemterved and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC)	published	178	2024	https://reports.altix.at/1522/
Tislelizumab (Tisleori®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)	published	179	2024	https://reports.altix.at/1523/
Erdafitinib (Erdafinib®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)	published	180	2024	https://reports.altix.at/1531/
Ochronelemab (Ochrone®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (in FL) or diffuse large B-cell lymphoma (in DLBCL)	published	181	2024	https://reports.altix.at/1532/
Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC). Followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair-deficient (dMMR) or in combination with cisplatin (Lumpra®) in EC that is mismatch repair-deficient (dMMR)	published	182	2024	https://reports.altix.at/1533/
Eccoritamab (Tectiniv®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)	published	183	2024	https://reports.altix.at/1534/
Toripalimab (Lodotz®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC)	published	184	2024	https://reports.altix.at/1537/
Toripalimab (Lodotz®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent or metastatic oropharyngeal squamous cell carcinoma (OSCC)	published	185	2024	https://reports.altix.at/1538/
Zolbetuximab (Zynliva®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma	published	186	2024	https://reports.altix.at/1539/
Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC)	published	187	2024	https://reports.altix.at/1540/
Pembrolizumab (Keytruda®) with enfortumab vedotin (Polaris®) for the first-line treatment of unresectable or metastatic urothelial carcinoma	published	188	2024	https://reports.altix.at/1541/
Amivantamab (Rybrevant®) in combination with carboplatin and pemterved for the treatment of advanced non-small cell lung cancer (NSCLC)	published	189	2024	https://reports.altix.at/1542/

Title	Status	No.	Year	DownloadLink
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC	published	190	2024	https://eprints.aitha.at/1543/
Daratumumab (Darzalex®) with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM)	published	191	2024	https://eprints.aitha.at/1550/
Serplunimab (Hetero®) with carboplatin and etoposide for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	published	192	2024	https://eprints.aitha.at/1551/
Mirvetuximab soravudine (Elahere®) for the treatment of adults with folate receptor-alpha (FR α) positive epithelial ovarian, fallopian tube and primary peritoneal cancer	published	193	2024	https://eprints.aitha.at/1552/
Pembrolizumab (Keytruda®) with chemoradiotherapy (CRT) for the treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer	published	194	2024	https://eprints.aitha.at/1553/
Pembrolizumab (Keytruda®) for the treatment of adults with endometrial carcinoma	published	195	2024	https://eprints.aitha.at/1554/
Catumaxomab (Kojun®) for the treatment of malignant ascites	published	196	2025	https://eprints.aitha.at/1579/
Tislelizumab (Tevimbra®) with platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic oesophagoesophageal squamous cell carcinoma	published	198	2025	https://eprints.aitha.at/1579/
Tislelizumab (Tevimbra®) with chemotherapy for the first-line treatment of HER-2-negative locally advanced unresectable or metastatic gastroesophageal junction adenocarcinoma	published	199	2025	https://eprints.aitha.at/1582/
Pembrolizumab (Keytruda®) for the treatment of malignant pleural mesothelioma	published	202	2025	https://eprints.aitha.at/1583/
Blinatumumab (Blincyto®) monotherapy as part of consolidation therapy for the treatment of adult patients with Philadelphia chromosome-negative (Ph \neg) CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL)	published	208	2025	https://eprints.aitha.at/1584/
Dabrafenib derivatecan (Dafway®) for the treatment of unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer	published	210	2025	https://eprints.aitha.at/1580/
Lisocabtagene maraleucel (Breyni®) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy	published	212	2025	https://eprints.aitha.at/1589/
Tislelizumab (Tevimbra®) with etoposide and platinum chemotherapy for the first-line treatment of extensive-stage small cell lung cancer	published	225	2025	https://eprints.aitha.at/1585/
Tislelizumab (Tevimbra®) in combination with pembrolizumab and osimertinib for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma	published	233	2025	https://eprints.aitha.at/1596/
Tislelizumab (Tevimbra®) with platinum-containing chemotherapy as re-adjunct treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer	published	241	2025	https://eprints.aitha.at/1587/
Other Annual Reports				
Annual Report 2006, German version	published		2007	http://eprints.aitha.at/781/
Annual Report 2006, English version	published		2007	http://eprints.aitha.at/780/
Annual Report 2007, German version	published		2008	http://eprints.aitha.at/782/
Annual Report 2007, English version	published		2008	http://eprints.aitha.at/785/
Annual Report 2008, German version	published		2009	http://eprints.aitha.at/819/
Annual Report 2008, English version	published		2009	http://eprints.aitha.at/821/
Annual Report 2009, German version	published		2010	http://eprints.aitha.at/871/
Annual Report 2009, English version	published		2010	http://eprints.aitha.at/872/
Annual Report 2010, German version	published		2011	http://eprints.aitha.at/904/
Annual Report 2010, English version	published		2011	http://eprints.aitha.at/909/
Annual Report 2011, German version	published		2012	http://eprints.aitha.at/943/
Annual Report 2011, English version	published		2012	http://eprints.aitha.at/944/
"Institut für Health Technology Assessment" unter Mitfinanzierung der Ludwig Boltzmann Gesellschaft 2013-2020	finished		2010	not published
"Institute for Health Technology Assessment" with Co-financing of the Ludwig Boltzmann Gesellschaft 2013 bis 2020	finished		2011	not published
Annual Report 2012, German/English	published		2013	http://eprints.aitha.at/991/
Annual Report 2013, German/English	published		2014	http://eprints.aitha.at/1052/
Annual Report 2014, German/English	published		2015	http://eprints.aitha.at/1048/
Annual Report 2015, German/English	published		2016	http://eprints.aitha.at/1083/
Annual Report 2016, German/English	published		2017	http://eprints.aitha.at/1150/
Annual Report 2017, German/English	published		2018	http://eprints.aitha.at/1151/
Annual Report 2018, German/English	published		2019	http://eprints.aitha.at/1187/
Annual Report 2019, German/English	published		2020	http://eprints.aitha.at/1228/
Annual Report 2020, German/English	published		2021	https://eprints.aitha.at/1294/
Annual Report 2021, German/English	published		2022	https://eprints.aitha.at/1358/
Annual Report 2022, German/English	published		2023	https://eprints.aitha.at/1423/
Annual Report 2023, German/English	published		2024	https://eprints.aitha.at/1501/
Annual Report 2024, German/English	published		2025	https://eprints.aitha.at/1557/

Title	Status	No.	Year	DownloadLink
EUneHTA (European network for Health Technology Assessment) Joint Action 1 - Lead Partner Work package 7B - New Technologies	ongoing		2006-2008, 2009, 2010-2013	www.eunehta.eu/
EUneHTA (European network for Health Technology Assessment) Joint Action 2 - Co-lead Partner Work package 5 - Collaboration	ongoing		2012-2015	www.eunehta.eu/
AHTageHTA	ongoing		2012-2015	http://www.ahtagehta.eu/
HSG Priorisation No. 18	published		2014	http://reports.ahta.at/1028/
HSG Priorisation No. 19	published		2014	http://reports.ahta.at/1033/
HSG Priorisation No. 20	published		2014	http://reports.ahta.at/1040/
HSG Priorisation No. 21	published		2015	http://reports.ahta.at/1046/
HSG Priorisation No. 22	published		2015	http://reports.ahta.at/1052/
HSG Priorisation No. 23	published		2015	http://reports.ahta.at/1065/
HSG Priorisation No. 24	published		2015	http://reports.ahta.at/1074/
HSG Priorisation No. 25	published		2016	http://reports.ahta.at/1079/
HSG Priorisation No. 26	published		2016	http://reports.ahta.at/1087/
HSG Priorisation No. 27	published		2016	http://reports.ahta.at/1099/
HSG Priorisation No. 28	published		2016	http://reports.ahta.at/1106/
HSG Priorisation No. 29	published		2017	http://reports.ahta.at/1113/
HSG Priorisation No. 30	published		2017	http://reports.ahta.at/1117/
HSG Priorisation No. 31	published		2017	http://reports.ahta.at/1121/
HSG Priorisation No. 32	published		2017	http://reports.ahta.at/1133/
HSG Priorisation No. 33	published		2018	http://reports.ahta.at/1135/
HSG Priorisation No. 34	published		2018	http://reports.ahta.at/1149/
HSG Priorisation No. 35	published		2018	http://reports.ahta.at/1156/
HSG Priorisation No. 36	published		2018	http://reports.ahta.at/1162/
HSG Priorisation No. 37	published		2018	http://reports.ahta.at/1179/
HSG Priorisation No. 38	published		2019	http://reports.ahta.at/1189/
HSG Priorisation No. 39	published		2019	http://reports.ahta.at/1196/
HSG Priorisation No. 40	published		2019	http://reports.ahta.at/1208/
HSG Priorisation No. 41	published		2020	http://reports.ahta.at/1229/